A randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis

Lieberman, Jay; Zhang, Jie; Whitworth, John; Cavender, Cary P.

doi:10.1016/j.anai.2018.03.006

Cited by 33 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cromolyn sodium or disodium cromoglicate is a mast cell stabilizer from the chromones class, able to suppress activation and degranulation by inhibiting calcium ion influx. Although animal model studies based on subcutaneous OVA sensitization followed by oral challenge showed some effects on eosinophilic and mast cell influx, collagen deposition, mast cell activation and Th2 immune response ( Silva et al, 2020 ), a small randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium in children with EoE found no effect on eosinophilic infiltrate and symptoms ( Lieberman et al, 2018 ).…”

Section: Focus On Type 2 Inflammation: the Protagonistsmentioning

confidence: 99%

Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets

et al. 2022

View full text Add to dashboard Cite

Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease of the esophagus characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation, whose incidence is rising. It significantly affects patients’ quality of life and, if left untreated, results in fibrotic complications. Although broad consensus has been achieved on first-line therapy, a subset of patients remains non-responder to standard therapy. The pathogenesis of EoE is multifactorial and results from the complex, still mostly undefined, interaction between genetics and intrinsic factors, environment, and antigenic stimuli. A deep understanding of the pathophysiology of this disease is pivotal for the development of new therapies. This review provides a comprehensive description of the pathophysiology of EoE, starting from major pathogenic mechanisms (genetics, type 2 inflammation, epithelial barrier dysfunction, gastroesophageal reflux, allergens, infections and microbiota) and subsequently focusing on the single protagonists of type 2 inflammation (involved cells, cytokines, soluble effectors, surface proteins and transcription factors) that could represent present and future therapeutic targets, while summarizing previous therapeutic approaches in literature.

show abstract

Section: Focus On Type 2 Inflammation: the Protagonistsmentioning

confidence: 99%

Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets

et al. 2022

View full text Add to dashboard Cite

show abstract

“…8 Sodium cromoglycate (SCG) is an effective drug for the treatment of disorders associated with type I hypersensitivity reactions accompanied by mast cell degranulation and its importance in the management of asthma is accepted widely. 9,10 As there is evidence of tissue eosinophilia and mast cell activity followed by increased histamine secretion in UC patients 11 and a lower incidence of side effects by cromolyn administration compared to glucocorticoids and aminosalicylate, 12 it was believed that SCG might be valuable in UC management. This study evaluated the impact of SCG on AA-induced UC through a com-parison of sulfasalazine (SSZ) treatment as a standard procedure.…”

Section: Introductionmentioning

confidence: 99%

Effect of Sodium Cromoglycate on Acetic Acid-induced Ulcerative Colitis in Mice

Ghafouri

Seyyedian

Nikbakht

et al. 2020

Korean J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: Ulcerative colitis (UC) is a type of inflammatory bowel disease that mainly involves the colon. Thus far, glucocorticoids and amino-salicylate have been the main treatment. Methods: To assess drugs with fewer side effects, this study evaluated the effects of sodium cromoglycate (SCG) on acetic acid-induced UC in rats. The treatment groups included SCG receivers (50 and 100 mg/kg, intra-orally) and sulfasalazine (SSZ) receivers (100 mg/kg, intra-orally). The colonic mucosal injury was assessed by clinical, macroscopic, and histopathological examinations. Results: In the treatment groups with 50 and 100 mg/kg of SCG, the clinical activity score decreased to 2.67±0.18 and 1.73±0.21 (p<0.05), respectively, compared to the UC control group (3.21±0.31), and were higher than that of the group given the standard treatment of 100 mg/kg SSZ (1.10±0.09). The treatment groups with 50 and 100 mg/kg of SCG showed a lower clinical gross lesion score than the UC control group (2.91±0.28 and 2.10±0.43, vs. 4.49±0.61, p<0.05) and were higher than the standard group (0.95±0.18). Treatment with SCG (100 mg/kg) decreased the macroscopic scores significantly compared to the UC control group (p<0.05) on the 8th day. Conclusions: SCG (100mg/kg) decreased significantly the clinical activity score, gross lesion, and percentage-affected area compared to the UC controls on the 8th day.

show abstract

“…Howver, PPIs may still be used to help distinguish gastroesophageal reflux from EoE because the symptoms overlap extensively, particularly in pediatric populations. An alternative therapy is the use of oral cromolyn, which was reported by Lieberman and colleagues 59 in a doubleblind study published in the May 2018 issue. Sixteen patients were enrolled in the study, with 9 randomized to active and 7 to placebo, without any improvement in the esophageal eosinophil count in either arm.…”

Section: Eosinophilic Gastrointestinal Diseasementioning

confidence: 98%

The Best of 2018 in the Annals of Allergy, Asthma, and Immunology

Marshall

Leung

Ellis

et al. 2019

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

The editors of the Annals of Allergy, Asthma, and Immunology considered more than 750 submissions for publication in 2018. From that number, we accepted 323 articles, letters, and other features to be included in the 12 issues of the 2018 Annals. Every feature was carefully scrutinized before acceptance, and there were multiple articles that were acceptable but were not used because of space constraints (ie, we do not have room to publish all of the acceptable manuscripts we received). Accordingly, the 323 are already the "best" of the submissions that were submitted last year. We are grateful to all the authors who submitted and those whose articles were published. At the end of the year, all the Annals editors provided their assessments of features published in the Annals from various areas of our specialty based on the individual interests and expertise of the editors. The results of these efforts produced mentions of the "best of the best" that we want to make sure you, our readership, had the opportunity to see, and we hope, read. The following is written with this aim in mind. Atopic DermatitisDuring the past year, there have been several highlighted themes on atopic dermatitis (AD) published in the Annals. Importantly, the multidimensional burden of AD was well documented, 1 including the effect of AD on quality of life, low self-esteem, increased sick days, reduced physical activity, and adverse effects

show abstract

A randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis

Cited by 33 publications

References 22 publications

Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets

Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets

Effect of Sodium Cromoglycate on Acetic Acid-induced Ulcerative Colitis in Mice

The Best of 2018 in the Annals of Allergy, Asthma, and Immunology

Contact Info

Product

Resources

About